A coalition of 20 groups asks CMS to eliminate Medicare Part B cost sharing for biosimilars in a letter spearheaded by the Association for Accessible Medicines’ Biosimilars Council. The groups say their recommendation jibes with the president’s 2020 budget proposal, which calls for “harnessing payment and costsharing incentives to increase biosimilar adoption.” Beneficiaries currently pay 20% of drug costs in Part B, which covers physician administered drugs. Most beneficiaries pay for supplemental insurance that covers most of the 20% charge,...